Global Ganja Report

With Oklahoma’s passage of a medical marijuana law, advocacy organizations say there is now only one state in the entire union without some sort of legal provision for medicinal use of either herbal cannabis or cannabinoid extracts: Idaho. And with a governor's race this year, there may be hope even there. One by one, even the most culturally conservative states are succumbing to the demands of patients and the findings of science to pass laws to allow use of (at least) extracts containing cannabinoids, or (at most) actual herbaceous marijuana, for either medical or "recreational" purposes.

Reports indicate that promoters of a popular initiative for a medical marijuana law in Utah have won enough signatures to get their proposal before the state's voters in November. A far more restrictive law allowing use of CBD preparations is meanwhile before the state house. The ballot initiative would make the legislation basically irrelevant—but faces stiff opposition.

A medical marijuana initiative has won enough signatures to make the November ballot in Utah. But the state's medical association has launched its own campaign to oppose it—and is challenging the validity of the petition drive. With the governor also opposed, the initiative will face a tough fight.

The Supreme Court on June 20 ruled that evidence discovered in a police stop found to be illegal may still be used in court—with the caveat that the officers conducted their search after learning that the suspect had an outstanding arrest warrant. In a 5-3 ruling, the Supremes found that such searches do not violate the Fourth Amendment. The case, Utah v. Strieff, concerned Edward Strieff, who in December 2006 was stopped by an officer staking out a suspected drug-dealing location in South Salt Lake. Grounds for the stop were later ruled inadequate because it was not based on reasonable suspicion. During the stop, the officer ran a check and discovered Strieff had an outstanding warrant for a minor traffic violation, and conducted a search—finding a baggie full of methamphetamines and a pipe that was deemed paraphernalia. A district court later ruled that although the cop didn't have the right to stop Strieff, the evidence was admissible. The highest court in the land has now agreed.

British firm GW Pharmaceuticals has won "orphan drug status"—a special category for agents developed to treat rare diseases—from the US Food and Drug Administration (FDA) for Epidiolex, a derivative of cannabidiol (CBD), to treat Dravet syndrome, a severe form epilepsy. In Utah, parents who are lobbying to import CBD-rich cannabis strains from Colorado, say they will keep up their campaign. "This changes nothing" in regard to children being able to access CBD, said Jennifer May, mother of 11-year-old Stockton, who suffers from Dravet syndrome. "On the other hand, it does lend credibility to the potential of CBD as a treatment." Like many Dravet patients, Stockton has tried dozens of pharmaceutical fixes, and run out of options. He can no longer use the toilet and has to be fed from a tube. "Orphan drug" designation qualifies GW for tax credits and exclusive rights to the drug if approved. But FDA approval for Epidiolex could take a year or more. (Salt Lake Tribune, Nov. 18)